Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported that the FDA has granted priority review status to the new drug application for ixazomib, the first investigational oral proteasome inhibitor for the treatment of patients with relapsed or refractory multiple myeloma. Patients in the company’s pivotal phase III trial, TOURMALINE-MM1, continue to be treated to progression in this trial and will be evaluated for long-term outcomes.